236 related articles for article (PubMed ID: 22147859)
1. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
2. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
3. Confounding factors in off-label drug use.
Greenberg PE; Pike C; Sisitsky T
Health Aff (Millwood); 2012 Feb; 31(2):460; author reply 460. PubMed ID: 22323178
[No Abstract] [Full Text] [Related]
4. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
5. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
Krause JH
Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064
[TBL] [Abstract][Full Text] [Related]
6. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
7. Investigating pharmaceutical marketing in Canada using American prosecutions.
Shoucri R; Persaud N
Int J Risk Saf Med; 2014; 26(3):147-53. PubMed ID: 25214160
[TBL] [Abstract][Full Text] [Related]
8. Pfizer versus Kaiser: insurers want their day in court.
Silverman E
BMJ; 2013 Jun; 346():f3738. PubMed ID: 23760967
[No Abstract] [Full Text] [Related]
9. Off-label marketing: free speech or illegal promotion?
Silverman E
BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
[No Abstract] [Full Text] [Related]
10. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson A; Davis C; Mulinari S
PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
[TBL] [Abstract][Full Text] [Related]
11. Media coverage of off-label promotion: a content analysis of US newspapers.
Joshi AD; Patel DA; Holdford DA
Res Social Adm Pharm; 2011 Sep; 7(3):257-71. PubMed ID: 21272550
[TBL] [Abstract][Full Text] [Related]
12. Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
Ghinea N; Lipworth W; Kerridge I
J Eval Clin Pract; 2015 Feb; 21(1):28-33. PubMed ID: 24986307
[TBL] [Abstract][Full Text] [Related]
13. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Vedula SS; Goldman PS; Rona IJ; Greene TM; Dickersin K
Trials; 2012 Aug; 13():136. PubMed ID: 22888801
[TBL] [Abstract][Full Text] [Related]
14. Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.
Melvin CL; Ranney LM; Carey TS; Evans WD; AED Dissemination Panel ; Kreps G; Linden T; Oldham J
J Psychiatr Pract; 2008 Mar; 14 Suppl 1():44-56. PubMed ID: 19034209
[TBL] [Abstract][Full Text] [Related]
15. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
Larkin I; Ang D; Avorn J; Kesselheim AS
Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
[TBL] [Abstract][Full Text] [Related]
16. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
Gilhooley M
Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
[TBL] [Abstract][Full Text] [Related]
17. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
[No Abstract] [Full Text] [Related]
18. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.
Fullerton CA; Busch AB; Frank RG
Med Care; 2010 Apr; 48(4):372-9. PubMed ID: 20195173
[TBL] [Abstract][Full Text] [Related]
19. Off-label marketing and the First Amendment.
Boumil MM
N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
[No Abstract] [Full Text] [Related]
20. Off-label prescribing among office-based physicians.
Radley DC; Finkelstein SN; Stafford RS
Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
